why choose us

Course: Administration of Anti–SARS-CoV-2 Monoclonal Antibodies After US Food and Drug Administration Deauthorization

CME Credits: 1.00

Released: 2022-08-29

In 2021, the US Food and Drug Administration (FDA) issued emergency use authorizations for 2 anti–SARS-CoV-2 monoclonal antibodies (mAbs), bamlanivimab-etesevimab and casirivimab-imdevimab, to treat mild to moderate COVID-19 in high-risk ambulatory patients. The Omicron variant was determined to not be susceptible to these treatments, leading the FDA to deauthorize their use on January 24, 2022. Given public controversy over this decision, we evaluated the administration of bamlanivimab-etesevimab and casirivimab-imdevimab in the US after FDA deauthorization.


Educational Objective
To identify the key insights or developments described in this article


View Full Course